Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Trial of Atezolizumab Plus Induction Chemotherapy (CT) Plus Chemo-radiotherapy and Atezolizumab Maintenance Therapy in Non-resectable Stage IIIA-IIIB Non-small Cell Lung Cancer (NSCLC) Patients

NCT04776447 is registered in ClinicalTrials.gov with Fundación GECP as lead sponsor.

NCT NCT04776447
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04776447 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Trial of Atezolizumab Plus Induction Chemotherapy (CT) Plus Chemo-radiotherapy and Atezolizumab Maintenance Therapy in Non-resectable Stage IIIA-IIIB Non-small Cell Lung Cancer (NSCLC) Patients
Lead sponsor
Fundación GECP
Phase
Phase 2
Overall status
Completed
Start date
June 16, 2021
Completion date
July 31, 2025
Enrollment
38 (actual)
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma bronchiogenic stage iii, carcinoma, non-small-cell lung, lung diseases, respiratory tract neoplasms, stage iiia non-small cell lung cancer, stage iiib non-small cell lung cancer, thoracic neoplasms